Please assess the completion status of the following clinical trial:

Trial Title: PRogrammed Versus Modified Natural Cycle After Euploid Failed Embryo Transfer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Major Inclusion Criteria: The following are major inclusion criteria:~1. Patients planning to undergo frozen embryo transfer cycle with a single euploid blastocyst.~2. Patients who have previously undergone their first unsuccessful frozen embryo transfer cycle, defined as either failure of implantation with negative pregnancy test or biochemical pregnancy, using a programmed cycle protocol.~3. Preimplantation genetic testing for aneuploidy (PGT-A) of the embryo used in failed programmed embryo transfer cycle must have occurred after January 1, 2017.~4. Patients ages 18 to 53 years old as per practice guidelines.~5. Patients with BMI between 16-45 kg/m2.~6. Patients with at least one embryo remaining in storage, from either the same or a separate cohort.~7. Patients with proven ovulatory function, as defined by the presence of regular menstrual cycles or detection of luteinizing hormone surge on serum or urinary test kits.~8. Patients with ≥ 7 mm endometrial thickness prior to progesterone start in prior transfer cycle.~9. Normal uterine cavity as evidenced by recent (within 1 year) saline sonogram or hysteroscopy.~Major Exclusion Criteria: The following are exclusion criteria:~1. More than 1 prior unsuccessful frozen embryo transfer cycle.~2. The prior FET failure having had resulted in a clinical loss or ectopic pregnancy~3. Previously cancelled frozen embryo transfer cycle for inadequate endometrial response.~4. Patients who required a different route of estrogen administration in the prior programmed cycle (vaginal, transdermal, intramuscular).~5. PGT-A analysis of the available embryo for transfer performed prior to January 1, 2017.~6. Anovulatory or oligo-ovulatory patients unable to undergo modified natural endometrial preparation.~7. Patients with an endometrial thickness \< 7 mm prior to progesterone start in prior cycle.~8. History of hypertensive disorders of pregnancy, including gestational hypertension, preeclampsia, and eclampsia.~9. Mullerian anomalies, excluding arcuate uterus and repaired septum.~10. No euploid embryos available for transfer.~11. Concurrent submucosal fibroids, unrepaired uterine defects or present indication for uterine surgery.~12. Communicating hydrosalpinx without plans for surgical correction prior to study enrollment.~13. Failure of patient to agree to enrollment in study with written consent.~14. Concurrent pregnancy.~15. Concomitant use of adjunctive therapies for endometrial proliferation or receptivity, including anticoagulation and antihistamines. These must be discontinued upon enrollment.~16. Embryo planned to be used for transfer generated from surgically obtained sperm.~17. Recurrent/persistent endometrial fluid in prior cycles visualized on the majority of transvaginal ultrasound monitoring.~18. Third party reproduction patients (donor sperm sources can be included).

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 53 Years
- Healthy Volunteers: f

Study Arms:
- Programmed FET Protocol (Type: OTHER): Patients in this arm of the study will proceed with another programmed FET protocol which involves taking exogenous estrogen by mouth to stimulate the uterine lining to grow and develop. Once the lining has reached ≥ 7 mm and an endometrial pattern of type 1 or type 2, intramuscular progesterone in oil (50mg/ml daily) will be started at 8am on the morning that progesterone is initiated and continued per routine.
- Modified Natural FET Protocol (Type: OTHER): Following development of at least one dominant follicle and endometrial proliferation ≥ 7 mm during cycle monitoring, patient will undergo administration of human chorionic gonadotropin (hCG) trigger shot followed by initiation of vaginal progesterone administration in accordance with institutional protocols.

Based on this trial design, predict the completion outcome and termination type (if applicable).